Effects of age and dysfunction on human meibomian glands

Archives of Ophthalmology

Volumn 129, Issue 4, 2011, Pages 462-469

  Nien, Chyong Jy ^a   Massei, Salina ^a   Lin, Gloria ^a   Nabavi, Cameron ^a   Tao, Jeremiah ^a   Brown, Donald J ^a   Paugh, Jerry R ^b   Jester, James V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SOUTHERN CALIFORNIA COLLEGE OF OPTOMETRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACINAR CELL; ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CYTOPLASM; EYELID DISEASE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEIBOMIAN GLAND; MEIBOMIAN GLAND DISEASE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIGENS, CD45; CELL DIFFERENTIATION; CELL PROLIFERATION; EYELID DISEASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KI-67 ANTIGEN; MALE; MEIBOMIAN GLANDS; MIDDLE AGED; PPAR GAMMA;

EID: 79953881846     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.69     Document Type: Article

References (51)

1. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7(2)(suppl):S1-S14.
2. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of Meibomian gland dysfunction. Optom Vis Sci. 1990;67(9):710-712. (Pubitemid 20354631)
3. Ong BL. Relation between contact lens wear and Meibomian gland dysfunction. Optom Vis Sci. 1996;73(3):208-210.
4. Ong BL, Larke JR.Meibomian gland dysfunction: some clinical, biochemical and physical observations. Ophthalmic Physiol Opt. 1990;10(2):144-148. (Pubitemid 20167980)
5. Mishima S, Maurice DM. The oily layer of the tear film and evaporation from the corneal surface. Exp Eye Res. 1961;1:39-45.
6. Gilbard JP, Rossi SR, Heyda KG. Tear film and ocular surface changes after closure of the meibomian gland orifices in the rabbit. Ophthalmology. 1989;96 (8):1180-1186. (Pubitemid 19196065)
7. McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer. Ocul Surf. 2003;1(3):97-106. (Pubitemid 41263899)
8. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol. 1995;113(10): 1266-1270.
9. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1(3):107-126. (Pubitemid 41263900)
10. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol. 1982;94(3):383-387. (Pubitemid 12054433)
11. Jester JV, Nicolaides N, Kiss-Palvolgyi I, Smith RE. Meibomian gland dysfunction II: the role of keratinization in a rabbit model of MGD. Invest Ophthalmol Vis Sci. 1989;30(5):936-945. (Pubitemid 19140187)
12. Jester JV, Rajagopalan S, Rodrigues M. Meibomian gland changes in the rhino (hrrhhrrh) mouse. Invest Ophthalmol Vis Sci. 1988;29(7):1190-1194.
13. Jester JV, Rife L, Nii D, Luttrull JK, Wilson L, Smith RE. In vivo biomicroscopy and photography of meibomian glands in a rabbit model of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 1982;22(5):660-667. (Pubitemid 12075372)
14. Ohnishi Y, Kohno T. Polychlorinated biphenyls poisoning in monkey eye. Invest Ophthalmol Vis Sci. 1979;18(9):981-984. (Pubitemid 9245149)
15. Guillon M, Maïssa C. Tear film evaporation: effect of age and gender. Cont Lens Anterior Eye. 2010;33(4):171-175.
16. Maïssa C, Guillon M. Tear film dynamics and lipid layer characteristics: effect of age and gender. Cont Lens Anterior Eye. 2010;33(4):176-182.
17. Hykin PG, Bron AJ. Age-related morphological changes in lid margin and meibomian gland anatomy. Cornea. 1992;11(4):334-342.
18. Obata H. Anatomy and histopathology of human meibomian gland. Cornea. 2002; 21(7)(suppl):S70-S74.
19. Nien CJ, Paugh JR, Massei S, Wahlert AJ, Kao WW, Jester JV. Age-related changes in the meibomian gland. Exp Eye Res. 2009;89(6):1021-1027.
20. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276(41):37731-37734.
21. Nien CJ, Massei SR, Lin G, et al. The development of meibomian glands in mice. Mol Vis. 2010;16:1132-1140.
22. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4(4):611-617. (Pubitemid 29531140)
23. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV.Meibomian gland dysfunction in chronic blepharitis. Cornea. 1991;10(4):277-285.
24. Nichols JJ, Berntsen DA, Mitchell GL, Nichols KK. An assessment of grading scales for meibography images. Cornea. 2005;24(4):382-388. (Pubitemid 40586624)
25. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev. 2000;14(11):1293-1307. (Pubitemid 30397073)
26. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341-367. (Pubitemid 32662214)
27. Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids. 2005;73(1):65-75. (Pubitemid 40826930)
28. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289-312.
29. Fan W, Yanase T, Nomura M, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes. 2005;54(4):1000-1008. (Pubitemid 40450323)
30. Ciana P, Biserni A, Tatangelo L, et al. A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Mol Endocrinol. 2009;21:388-400. (Pubitemid 46184892)
31. Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5alphadihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol. 2007;156(3):428-432.
32. Halvorsen B, Heggen E, Ueland T, et al. Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol. 2010;162(2):267-273.
33. Moulin D, Bianchi A, Boyault S, et al. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1 beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Arthritis Rheum. 2005;52:759-769. (Pubitemid 40365097)
34. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs. 2004;13(3):215-228. (Pubitemid 38351343)
35. Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci. 2000;41(12):3732-3742.
36. Schirra F, Suzuki T, Richards SM, et al. Androgen control of gene expression in the mouse meibomian gland. Invest Ophthalmol Vis Sci. 2005;46(10):3666-3675. (Pubitemid 44264671)
37. Richards SM, Yamagami H, Schirra F, Suzuki T, Jensen RV, Sullivan DA. Sexrelated effect on gene expression in the mouse meibomian gland. Curr Eye Res. 2006;31(2):119-128.
38. Sullivan DA. Tearful relationships? sex, hormones, the lacrimal gland, and aqueousdeficient dry eye. Ocul Surf. 2004;2(2):92-123. (Pubitemid 41263878)
39. Sullivan BD, Evans JE, Cermak JM, Krenzer KL, Dana MR, Sullivan DA. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Arch Ophthalmol. 2002;120(12):1689-1699. (Pubitemid 36401805)
40. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211-222. (Pubitemid 34729176)
41. Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface? Cornea. 2003;22(6):516-521. (Pubitemid 36909729)
42. Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. Ocul Surf. 2010;8(1):18-28.
43. Afonso AA, Monroy D, Stern ME, Feuer WJ, Tseng SC, Pflugfelder SC. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology. 1999;106(4):803-810. (Pubitemid 30194326)
44. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283-2292. (Pubitemid 32848857)
45. Pflugfelder SC, Stern ME; Symposium Participants. Immunoregulation on the ocular surface: 2nd Cullen symposium. Ocul Surf. 2009;7(2):67-77.
46. Lambert RW, Smith RE. Pathogenesis of blepharoconjunctivitis complicating 13- cis-retinoic acid (isotretinoin) therapy in a laboratory model. Invest Ophthalmol Vis Sci. 1988;29(10):1559-1564.
47. Lambert RW, Smith RE. Effects of 13-cis-retinoic acid on the hamster meibomian gland. J Invest Dermatol. 1989;92(3):321-325. (Pubitemid 19079775)
48. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea. 1991; 10(4):286-290.
49. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.
50. Robin JB, Jester JV, Nobe J, Nicolaides N, Smith RE. In vivo transillumination biomicroscopy and photography of meibomian gland dysfunction: a clinical study. Ophthalmology. 1985;92(10):1423-1426. (Pubitemid 16193375)
51. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology. 1993;100(3):347-351. (Pubitemid 23088533)